Identification

Name
Tolazoline
Accession Number
DB00797  (APRD00170)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem]

Structure
Thumb
Synonyms
  • 2-Benzyl-2-imidazoline
  • 2-Benzyl-4,5-imidazoline
  • 2-Benzylimidazoline
  • 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole
  • Benzazolin
  • Tolazolin
  • Tolazolina
  • Tolazoline
  • Tolazolinum
Product Ingredients
IngredientUNIICASInChI Key
Benzazoline hydrochlorideNot AvailableNot AvailableNot applicable
Tolazoline HydrochlorideE669Z6S1JG59-97-2RHTNTTODYGNRSP-UHFFFAOYSA-N
International/Other Brands
Divascol (VUAB Pharma) / Imidalin (Astellas Pharma)
Categories
UNII
CHH9H12AQ3
CAS number
59-98-3
Weight
Average: 160.2157
Monoisotopic: 160.100048394
Chemical Formula
C10H12N2
InChI Key
JIVZKJJQOZQXQB-UHFFFAOYSA-N
InChI
InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)
IUPAC Name
2-benzyl-4,5-dihydro-1H-imidazole
SMILES
C(C1=NCCN1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of pulmonary artery anomalies

Pharmacodynamics

Tolazoline is a pulmonary vasodilator indicated used to decrease pulmonary vascular resistance (PVR) in persistent pulmonary hypertension of the newborn (PPHN).

Mechanism of action

Vasodilation by means of a direct effect on peripheral vascular smooth muscle and indirect effects produced, in part, by release of endogenous histamine; tolazoline has moderate alpha-adrenergic blocking activity and has histamine agonist activity. Tolazoline usually reduces pulmonary arterial pressure and vascular resistance.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UHistamine H1 receptor
agonist
Human
UHistamine H2 receptor
agonist
Human
UAlpha-2C adrenergic receptor
binder
Human
UAlpha-2B adrenergic receptor
binder
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineTolazoline may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Tolazoline.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
AcemetacinThe therapeutic efficacy of Tolazoline can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineTolazoline may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AdrafinilTolazoline may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineTolazoline may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Tolazoline is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Tolazoline.Approved, Investigational
AliskirenTolazoline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Withdrawn
AmbrisentanTolazoline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronTolazoline may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineTolazoline may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Tolazoline is combined with Amiloride.Approved
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
AmitrazTolazoline may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineTolazoline may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Tolazoline is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Tolazoline.Approved, Illicit
AmoxapineTolazoline may increase the antihypertensive activities of Amoxapine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Tolazoline.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolazoline.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Tolazoline is combined with Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Tolazoline is combined with Amyl Nitrite.Approved
AnisodamineTolazoline may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Tolazoline.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Tolazoline is combined with Aranidipine.Approved, Investigational
ArbutamineTolazoline may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolTolazoline may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Tolazoline.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Tolazoline.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tolazoline.Approved, Investigational
AsenapineTolazoline may increase the antihypertensive activities of Asenapine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
AvanafilAvanafil may increase the hypotensive activities of Tolazoline.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Tolazoline is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Tolazoline is combined with Azilsartan medoxomil.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Tolazoline is combined with Azimilide.Investigational
BambuterolTolazoline may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Tolazoline.Experimental
BarbitalBarbital may increase the hypotensive activities of Tolazoline.Illicit
BarnidipineTolazoline may increase the antihypertensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Tolazoline.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Tolazoline is combined with Bencyclane.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Tolazoline.Approved
BenidipineThe risk or severity of hypotension can be increased when Tolazoline is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Tolazoline.Withdrawn
BenzphetamineTolazoline may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
BepridilTolazoline may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Tolazoline.Approved
BevantololTolazoline may increase the antihypertensive activities of Bevantolol.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Tolazoline.Experimental
BimatoprostTolazoline may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Tolazoline is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
BitolterolTolazoline may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Tolazoline.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Tolazoline.Approved, Investigational
BQ-123Tolazoline may increase the hypotensive activities of BQ-123.Investigational
BretyliumTolazoline may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleTolazoline may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Tolazoline.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Tolazoline.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolazoline.Approved, Investigational
BucindololBucindolol may increase the antihypertensive activities of Tolazoline.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Tolazoline.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Tolazoline is combined with Bumetanide.Approved
BunazosinBunazosin may increase the antihypertensive activities of Tolazoline.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolazoline.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Tolazoline.Experimental
CafedrineTolazoline may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Tolazoline is combined with Canagliflozin.Approved
CandesartanTolazoline may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Tolazoline.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Tolazoline.Experimental
CaptoprilTolazoline may increase the hypotensive activities of Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tolazoline.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Tolazoline is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Tolazoline is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Tolazoline.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Tolazoline.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
ChlorothiazideTolazoline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineTolazoline may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Tolazoline.Approved
CicletanineTolazoline may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilTolazoline may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tolazoline.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Tolazoline is combined with Cinnarizine.Approved, Investigational
CirazolineTolazoline may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolTolazoline may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Tolazoline.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tolazoline.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Tolazoline.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Tolazoline.Experimental
ClozapineTolazoline may increase the antihypertensive activities of Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tolazoline.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Tolazoline.Approved
CyclandelateThe risk or severity of hypotension can be increased when Tolazoline is combined with Cyclandelate.Approved
CyclopenthiazideTolazoline may increase the hypotensive activities of Cyclopenthiazide.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Tolazoline is combined with Dapagliflozin.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Tolazoline.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tolazoline.Investigational
DarodipineThe risk or severity of hypotension can be increased when Tolazoline is combined with Darodipine.Experimental
DebrisoquinDebrisoquin may increase the hypotensive activities of Tolazoline.Approved, Investigational
DelaprilTolazoline may increase the hypotensive activities of Delapril.Investigational
DeserpidineTolazoline may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tolazoline.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
DetomidineTolazoline may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineTolazoline may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Tolazoline.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Tolazoline is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineTolazoline may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Tolazoline.Approved, Investigational
DihydroergotamineTolazoline may decrease the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Tolazoline.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Tolazoline is combined with Dinutuximab.Approved, Investigational
DipivefrinTolazoline may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Tolazoline.Approved
DL-MethylephedrineTolazoline may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineTolazoline may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineTolazoline may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DorzolamideTolazoline may increase the hypotensive activities of Dorzolamide.Approved
DotarizineThe risk or severity of hypotension can be increased when Tolazoline is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Tolazoline.Approved
DoxepinTolazoline may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineTolazoline may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DronedaroneTolazoline may increase the antihypertensive activities of Dronedarone.Approved
DroperidolTolazoline may increase the antihypertensive activities of Droperidol.Approved, Vet Approved
DroxidopaTolazoline may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineTolazoline may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineTolazoline may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Tolazoline is combined with Empagliflozin.Approved
EnalaprilatTolazoline may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Tolazoline.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Tolazoline.Experimental
EperisoneThe risk or severity of hypotension can be increased when Tolazoline is combined with Eperisone.Approved, Investigational
EphedraTolazoline may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineTolazoline may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineTolazoline may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineTolazoline may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Tolazoline is combined with Eplerenone.Approved
EpoprostenolTolazoline may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTolazoline may increase the hypotensive activities of Eprosartan.Approved
ErgonovineTolazoline may decrease the vasoconstricting activities of Ergonovine.Approved
ErgotamineTolazoline may decrease the vasoconstricting activities of Ergotamine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Tolazoline.Experimental
EscitalopramTolazoline may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Tolazoline is combined with Etacrynic acid.Approved, Investigational
EtafedrineTolazoline may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Tolazoline is combined with Ethosuximide.Approved
EtilefrineTolazoline may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidateTolazoline may decrease the vasoconstricting activities of Etomidate.Approved
FelodipineTolazoline may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Tolazoline is combined with Fendiline.Withdrawn
FenoldopamTolazoline may increase the hypotensive activities of Fenoldopam.Approved
FenoterolTolazoline may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Ferulic acidTolazoline may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolazoline.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Tolazoline is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Tolazoline is combined with Flunarizine.Approved
FlupentixolTolazoline may increase the antihypertensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Tolazoline is combined with Fluspirilene.Approved, Investigational
FormoterolTolazoline may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Tolazoline.Approved
FostamatinibFostamatinib may increase the hypotensive activities of Tolazoline.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Tolazoline.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Tolazoline is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Tolazoline is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Tolazoline is combined with Gallopamil.Investigational
GuanabenzGuanabenz may increase the hypotensive activities of Tolazoline.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Tolazoline.Approved
GuanazodineTolazoline may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTolazoline may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Tolazoline.Approved, Investigational
GuanoclorTolazoline may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTolazoline may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTolazoline may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tolazoline.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Tolazoline.Experimental
HexamethoniumTolazoline may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Tolazoline.Approved
HexoprenalineTolazoline may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineTolazoline may decrease the vasoconstricting activities of Higenamine.Investigational
HydralazineHydralazine may increase the hypotensive activities of Tolazoline.Approved
HydrochlorothiazideTolazoline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Tolazoline.Approved, Investigational
IloperidoneTolazoline may increase the antihypertensive activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Tolazoline.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolazoline.Investigational
ImipramineTolazoline may increase the antihypertensive activities of Imipramine.Approved
IndacaterolTolazoline may decrease the vasoconstricting activities of Indacaterol.Approved
IndapamideTolazoline may increase the hypotensive activities of Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Tolazoline.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Tolazoline.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Tolazoline.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Tolazoline.Withdrawn
IrbesartanTolazoline may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Tolazoline.Approved
IsoetarineTolazoline may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tolazoline.Approved, Vet Approved
IsomethepteneTolazoline may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineTolazoline may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Tolazoline is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Tolazoline is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Tolazoline.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Tolazoline.Investigational
LabetalolLabetalol may increase the antihypertensive activities of Tolazoline.Approved
LacidipineTolazoline may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Tolazoline is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Tolazoline.Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Tolazoline.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Tolazoline is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Tolazoline is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tolazoline.Approved, Investigational
LevodopaTolazoline may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosalbutamolTolazoline may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Tolazoline.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Tolazoline is combined with Lidoflazine.Experimental
LinsidomineTolazoline may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineTolazoline may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Tolazoline.Approved, Investigational
LofexidineTolazoline may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Tolazoline is combined with Loperamide.Approved
LosartanLosartan may increase the hypotensive activities of Tolazoline.Approved
MacitentanTolazoline may increase the hypotensive activities of Macitentan.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Tolazoline is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineTolazoline may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Tolazoline is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Tolazoline.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Tolazoline.Approved, Investigational
MedetomidineTolazoline may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MentholThe risk or severity of hypotension can be increased when Tolazoline is combined with Menthol.Approved
MephentermineTolazoline may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Tolazoline.Experimental
MetaraminolTolazoline may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethamphetamineTolazoline may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Tolazoline is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Tolazoline.Approved
MethoserpidineTolazoline may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineTolazoline may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
MethoxamineTolazoline may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineTolazoline may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Tolazoline is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Tolazoline is combined with Methyclothiazide.Approved
MethyldopaTolazoline may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Tolazoline.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Tolazoline.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Tolazoline.Approved
MetipranololTolazoline may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Tolazoline.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
MetyrosineTolazoline may increase the hypotensive activities of Metyrosine.Approved
MibefradilTolazoline may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineTolazoline may decrease the vasoconstricting activities of Midodrine.Approved
MinaprineMinaprine may increase the hypotensive activities of Tolazoline.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Tolazoline.Approved, Investigational
MirabegronTolazoline may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Tolazoline.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Tolazoline.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Tolazoline.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Tolazoline.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tolazoline.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Tolazoline.Approved, Investigational
MuzolimineTolazoline may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Tolazoline.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
NaftopidilTolazoline may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineTolazoline may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
NefazodoneTolazoline may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Tolazoline is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Tolazoline.Withdrawn
NicardipineTolazoline may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Tolazoline.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Tolazoline.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Nifedipine.Approved
NiguldipineTolazoline may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Tolazoline is combined with Niludipine.Experimental
NilvadipineTolazoline may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Tolazoline is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Tolazoline.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Tolazoline.Approved
NitrendipineTolazoline may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tolazoline.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Tolazoline is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Tolazoline.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Tolazoline.Approved, Investigational
NorepinephrineTolazoline may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineTolazoline may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylineTolazoline may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinTolazoline may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabTolazoline may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Tolazoline.Withdrawn
OctopamineTolazoline may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineTolazoline may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Tolazoline.Approved, Investigational
OlodaterolTolazoline may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatTolazoline may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineTolazoline may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Tolazoline is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
OxyfedrineTolazoline may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineTolazoline may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tolazoline.Approved, Vet Approved
PaliperidoneTolazoline may increase the antihypertensive activities of Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Papaverine.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Tolazoline.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Tolazoline.Approved, Investigational, Vet Approved
PentoliniumTolazoline may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Tolazoline.Approved, Investigational
PergolideTolazoline may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Tolazoline.Approved
PhendimetrazineTolazoline may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypotensive activities of Tolazoline.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Tolazoline.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Tolazoline.Approved, Investigational
PhenoxybenzamineTolazoline may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Tolazoline.Withdrawn
PhentolamineTolazoline may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineTolazoline may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineTolazoline may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilPinacidil may increase the hypotensive activities of Tolazoline.Approved
PinaveriumThe risk or severity of hypotension can be increased when Tolazoline is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tolazoline.Approved, Investigational
PirbuterolTolazoline may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Tolazoline.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Tolazoline.Withdrawn
PizotifenTolazoline may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Tolazoline.Experimental
PolythiazideTolazoline may increase the hypotensive activities of Polythiazide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tolazoline.Approved, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Tolazoline.Approved
PrenalterolTolazoline may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Tolazoline is combined with Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Tolazoline.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Tolazoline.Approved, Investigational
ProcaterolTolazoline may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazineTolazoline may increase the antihypertensive activities of Promazine.Approved, Vet Approved
PropafenonePropafenone may increase the orthostatic hypotensive activities of Tolazoline.Approved
PropericiazineTolazoline may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazineTolazoline may increase the antihypertensive activities of Propiomazine.Approved
PropiverineTolazoline may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tolazoline.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Investigational
ProtokylolTolazoline may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PseudoephedrineTolazoline may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineTolazoline may increase the antihypertensive activities of Quetiapine.Approved
QuinaprilTolazoline may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineTolazoline may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Tolazoline.Approved
RacepinephrineTolazoline may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineTolazoline may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilRamipril may increase the hypotensive activities of Tolazoline.Approved
RasagilineRasagiline may increase the hypotensive activities of Tolazoline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolazoline.Approved
RemikirenRemikiren may increase the hypotensive activities of Tolazoline.Approved
ReproterolTolazoline may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineTolazoline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Tolazoline.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Tolazoline.Approved, Investigational
RimiterolTolazoline may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatTolazoline may increase the hypotensive activities of Riociguat.Approved
RisperidoneTolazoline may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronTolazoline may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineTolazoline may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RituximabTolazoline may increase the hypotensive activities of Rituximab.Approved
RomifidineTolazoline may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Tolazoline.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolazoline.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Tolazoline.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tolazoline.Approved
SalbutamolTolazoline may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolTolazoline may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanTolazoline may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Tolazoline.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Tolazoline is combined with Seletracetam.Investigational
SelexipagTolazoline may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tolazoline.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Tolazoline.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Tolazoline.Approved
SitaxentanTolazoline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolabegronTolazoline may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Tolazoline.Approved
SpiraprilTolazoline may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Tolazoline is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Tolazoline.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolazoline.Approved, Investigational
SynephrineTolazoline may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Tolazoline.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Tolazoline.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Tolazoline.Approved, Investigational
TelmisartanTolazoline may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilTolazoline may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Tolazoline.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Tolazoline.Approved
TerlipressinTolazoline may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineThe risk or severity of hypotension can be increased when Tolazoline is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Tolazoline.Experimental
TetrahydropalmatineTolazoline may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineTolazoline may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tolazoline.Approved, Investigational, Withdrawn
TheodrenalineTolazoline may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the hypotensive activities of Tolazoline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
ThioproperazineTolazoline may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Tolazoline.Approved, Withdrawn
TiboloneTolazoline may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTolazoline may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Tolazoline.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Tizanidine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolazoline is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Tolazoline is combined with Tolfenamic Acid.Approved, Investigational
TolonidineTolazoline may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Tolazoline.Approved
TorasemideTorasemide may increase the hypotensive activities of Tolazoline.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Tolazoline.Approved
TranilastThe risk or severity of hypotension can be increased when Tolazoline is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Tolazoline.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Tolazoline.Approved
TrazodoneTolazoline may increase the antihypertensive activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Tolazoline.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tolazoline is combined with Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolTolazoline may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Tolazoline is combined with Triamterene.Approved
TrichlormethiazideTolazoline may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTolazoline may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Tolazoline.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Tolazoline is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Tolazoline is combined with Trimethadione.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Tolazoline.Approved, Investigational
TrimipramineTolazoline may increase the antihypertensive activities of Trimipramine.Approved
TulobuterolTolazoline may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Tolazoline.Approved, Investigational
UnoprostoneTolazoline may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Tolazoline.Investigational
ValsartanValsartan may increase the hypotensive activities of Tolazoline.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Tolazoline.Approved
VerapamilTolazoline may increase the antihypertensive activities of Verapamil.Approved
VilanterolTolazoline may decrease the vasoconstricting activities of Vilanterol.Approved
VincamineTolazoline may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTolazoline may increase the hypotensive activities of Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Tolazoline is combined with WIN 55212-2.Experimental
XamoterolTolazoline may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideTolazoline may increase the hypotensive activities of Xipamide.Experimental
XylazineTolazoline may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineTolazoline may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Tolazoline.Approved, Investigational, Vet Approved
ZiconotideThe risk or severity of hypotension can be increased when Tolazoline is combined with Ziconotide.Approved
ZiprasidoneZiprasidone may increase the antihypertensive activities of Tolazoline.Approved
ZofenoprilTolazoline may increase the hypotensive activities of Zofenopril.Experimental
ZonisamideThe risk or severity of hypotension can be increased when Tolazoline is combined with Zonisamide.Approved, Investigational
ZuclopenthixolTolazoline may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014935
KEGG Compound
C07147
PubChem Compound
5504
PubChem Substance
46505641
ChemSpider
5303
BindingDB
55436
ChEBI
28502
ChEMBL
CHEMBL770
Therapeutic Targets Database
DAP000477
PharmGKB
PA451716
Wikipedia
Tolazoline
ATC Codes
M02AX02 — TolazolineC04AB02 — Tolazoline
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
Packagers
  • Novartis AG
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)174 °CPhysProp
water solubility373 mg/LNot Available
logP2.65SANGSTER (1993)
pKa10.3SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility1.36 mg/mLALOGPS
logP2.05ALOGPS
logP1.2ChemAxon
logS-2.1ALOGPS
pKa (Strongest Basic)10.25ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.39 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity49.07 m3·mol-1ChemAxon
Polarizability17.94 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9821
Blood Brain Barrier+0.9334
Caco-2 permeable-0.5062
P-glycoprotein substrateSubstrate0.6249
P-glycoprotein inhibitor INon-inhibitor0.9707
P-glycoprotein inhibitor IINon-inhibitor0.9188
Renal organic cation transporterInhibitor0.7923
CYP450 2C9 substrateNon-substrate0.8404
CYP450 2D6 substrateSubstrate0.6912
CYP450 3A4 substrateNon-substrate0.8088
CYP450 1A2 substrateNon-inhibitor0.6013
CYP450 2C9 inhibitorNon-inhibitor0.9629
CYP450 2D6 inhibitorInhibitor0.7446
CYP450 2C19 inhibitorNon-inhibitor0.9844
CYP450 3A4 inhibitorNon-inhibitor0.9738
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9644
Ames testNon AMES toxic0.8569
CarcinogenicityNon-carcinogens0.9492
BiodegradationNot ready biodegradable0.9824
Rat acute toxicity2.5351 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7268
hERG inhibition (predictor II)Non-inhibitor0.8357
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.79 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0006-9400000000-7b6f1c4b249d1fba8927
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-0900000000-692cb3b89bff443fa65f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-0900000000-03a59847388e2e741709
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-4900000000-54d799a1c61663a2e513
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9100000000-c36b35a2866405756d0a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9000000000-c543ee9f104cc9558d70

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Imidolactam / Monocyclic benzene moiety / 2-imidazoline / Azacycle / Organoheterocyclic compound / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Carboxylic acid amidine / Amidine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles (CHEBI:28502)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Teskin O, Uydes-Dogan BS, Enc Y, Alp FI, Kaleli D, Keser S, Iyigun T, Bilgen F, Dagsali S, Ozdemir O: Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31. [PubMed:16368348]
  4. Song W, Zhang Y, Xia L, Liu G: [Effects of some mexiletine derivatives on alpha 1-adrenoceptors]. Yao Xue Xue Bao. 1998;33(2):102-5. [PubMed:11938943]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Song W, Zhang Y, Xia L, Liu G: [Effects of some mexiletine derivatives on alpha 1-adrenoceptors]. Yao Xue Xue Bao. 1998;33(2):102-5. [PubMed:11938943]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Roll C, Hanssler L: [Interaction of tolazoline and cimetidine in persistent fetal circulation of the newborn infant]. Monatsschr Kinderheilkd. 1993 Apr;141(4):297-9. [PubMed:8487790]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Ward RM: Pharmacology of tolazoline. Clin Perinatol. 1984 Oct;11(3):703-13. [PubMed:6386273]
  2. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]
  3. Roll C, Hanssler L: [Interaction of tolazoline and cimetidine in persistent fetal circulation of the newborn infant]. Monatsschr Kinderheilkd. 1993 Apr;141(4):297-9. [PubMed:8487790]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Trendelenburg AU, Sutej I, Starke K: Presynaptic alpha 2A/D-autoreceptors in the brain cortex of Cercopithecus aethiops. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):341-6. [PubMed:9089664]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Trendelenburg AU, Sutej I, Starke K: Presynaptic alpha 2A/D-autoreceptors in the brain cortex of Cercopithecus aethiops. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):341-6. [PubMed:9089664]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:46